Surrozen Past Earnings Performance
Past criteria checks 0/6
Surrozen's earnings have been declining at an average annual rate of -2.7%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 71.4% per year.
Key information
-2.7%
Earnings growth rate
30.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 71.4% |
| Return on equity | -124.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?
Jan 03
Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?
Jun 19Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely
Feb 12Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim
Oct 06Surrozen GAAP EPS of -$0.40 beats by $0.06
Aug 11Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)
Oct 14Revenue & Expenses Breakdown
How Surrozen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -38 | 14 | -3 |
| 31 Dec 23 | 0 | -43 | 16 | 0 |
| 30 Sep 23 | 13 | -35 | 17 | 8 |
| 30 Jun 23 | 13 | -38 | 19 | 8 |
| 31 Mar 23 | 13 | -42 | 20 | 8 |
| 31 Dec 22 | 13 | -36 | 20 | 0 |
| 30 Sep 22 | 0 | -50 | 19 | 0 |
| 30 Jun 22 | 0 | -51 | 17 | -19 |
| 31 Mar 22 | 0 | -50 | 15 | -9 |
| 31 Dec 21 | 0 | -55 | 14 | 0 |
| 30 Sep 21 | 0 | -51 | 12 | 9 |
| 30 Jun 21 | 0 | -45 | 11 | 34 |
| 31 Mar 21 | 0 | -39 | 10 | 30 |
| 31 Dec 20 | 0 | -33 | 7 | 26 |
Quality Earnings: SRZN is currently unprofitable.
Growing Profit Margin: SRZN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SRZN is unprofitable, and losses have increased over the past 5 years at a rate of 2.7% per year.
Accelerating Growth: Unable to compare SRZN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRZN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: SRZN has a negative Return on Equity (-124.68%), as it is currently unprofitable.